Sure, it's all a big surprise from that thing that
Post# of 147708
Nothing to do with NASH results forthcoming
Nothing to do with multiple Oncology revelations
Nothing to do with **3rd PO from Philippines**
Nothing to do with research partnerships with academic institutions
Nothing to do with investor conferences
Nothing to do with HGEN's EUA denial..
These are all new catalysts from the past week. None of those would cause anyone to re-evaluate CYDY's prospects, but that trial that was approved weeks ago, that was what finally did it.